Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1975 1
2003 1
2004 1
2008 1
2009 6
2010 11
2011 8
2012 11
2013 12
2014 12
2015 13
2016 8
2017 18
2018 25
2019 13
2020 10
2021 12
2022 11
2023 5
Text availability
Article attribute
Article type
Publication date

Search Results

150 results
Results by year
Filters applied: . Clear all
Page 1
Neutralizing monoclonal antibodies for treatment of COVID-19.
Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Taylor PC, et al. Among authors: de la torre i. Nat Rev Immunol. 2021 Jun;21(6):382-393. doi: 10.1038/s41577-021-00542-x. Epub 2021 Apr 19. Nat Rev Immunol. 2021. PMID: 33875867 Free PMC article. Review.
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, Hojnik M, Sapin C, Okada M, Caporali R, Gratacós J, Goupille P, Liu Leage S, Pillai S, Nash P. Smolen JS, et al. Among authors: de la torre i. Ann Rheum Dis. 2020 Oct;79(10):1310-1319. doi: 10.1136/annrheumdis-2020-217372. Epub 2020 Jul 13. Ann Rheum Dis. 2020. PMID: 32660977 Free PMC article. Clinical Trial.
Primate archaeology.
Haslam M, Hernandez-Aguilar A, Ling V, Carvalho S, de la Torre I, DeStefano A, Du A, Hardy B, Harris J, Marchant L, Matsuzawa T, McGrew W, Mercader J, Mora R, Petraglia M, Roche H, Visalberghi E, Warren R. Haslam M, et al. Among authors: de la torre i. Nature. 2009 Jul 16;460(7253):339-44. doi: 10.1038/nature08188. Nature. 2009. PMID: 19606139 Review.
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P. Dougados M, et al. Among authors: de la torre i. Ann Rheum Dis. 2017 Jan;76(1):88-95. doi: 10.1136/annrheumdis-2016-210094. Epub 2016 Sep 29. Ann Rheum Dis. 2017. PMID: 27689735 Free PMC article. Clinical Trial.
Preface.
de la Torre I, Hirata S. de la Torre I, et al. Philos Trans R Soc Lond B Biol Sci. 2015 Nov 19;370(1682):20150250. doi: 10.1098/rstb.2015.0250. Philos Trans R Soc Lond B Biol Sci. 2015. PMID: 26483539 Free PMC article. No abstract available.
Understanding the immunogenicity concept.
Valor L, de la Torre I. Valor L, et al. Among authors: de la torre i. Reumatol Clin. 2013 Jan-Feb;9(1):1-4. doi: 10.1016/j.reuma.2012.09.002. Epub 2012 Dec 21. Reumatol Clin. 2013. PMID: 23261343 Free article. English, Spanish. No abstract available.
150 results